The CRA role isn't shrinking. It's being elevated. For years, the job meant high-volume source data verification and box-checking against…

CluePoints

15,576 followers

The CRA role isn't shrinking. It's being elevated. For years, the job meant high-volume source data verification and box-checking against compliance. But as trials get more complex and data volumes climb, that model no longer fits. In his new piece for Applied Clinical Trials, CluePoints' Chi-Hui Tang, PhD makes the case for the CRA of the future: a data-enabled strategic partner to sites, not a manual monitor. His argument comes down to a few shifts worth sitting with: → Data only creates value when it drives the right action. Flooding sites with disconnected data points erodes trust. Consolidated analytics that separate signal from noise build it. → Fewer visits isn't the goal. Showing up for the right reasons is. Risk and site need should drive monitoring modality, not historical visit cadence. → Technology alone won't create the shift. New tools have to fit a clear operating model and be backed by real change management, or CRAs just end up with more dashboards and no new way of working. The takeaway for sponsors: this is an expansion of the CRA role, not a reduction. The organizations that lead the change will elevate site oversight. The ones that don't will keep paying for low-value activity that burdens sites and erodes trust. Worth a read for anyone thinking about RBQM maturity and ICH E6(R3) readiness. Read the full article here: https://hubs.ly/Q04tbByM0 #ClinicalTrials #RBQM #ClinicalResearch #ICHE6R3 #ClinicalOperations